Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose Furmonertinib or Combined With Chemotherapy in EGFR-mutated NSCLC
NCT06652048Phase 2
Key facts
- Status
- Recruiting
- Start
- Oct 2024
- Primary completion
- Dec 2026
- Countries
- 1
- Modality
- Small Molecules
- Drugs
- furmonertinib
- Conditions
- non-small cell lung cancer (NSCLC)
01
Overview
Phase 2, randomised, open-label trial of furmonertinib in non-small cell lung cancer (NSCLC) (3 arms). Primary endpoint: Progression-free survival at 2 years. Started Oct 2024; status: recruiting.
02
Design
3 arms- Study design
- RandomizedOpen-label
Furmonertinib 160mg
Furmonertinib 160mg p.o qd.
Furmonertinib 240mg
Furmonertinib 240mg p.o qd.
Furmonertinib 160mg + Chemo
Furmonertinib 160mg p.o qd + Carboplatin/Cisplatin + Pemetrexed followed by Pemetrexed maintenance.
03
Who it enrols
Patients with locally advanced or metastatic NSCLC with EGFR-sensitive mutations who progressed on first-line third-generation EGFR-TKI monotherapy.
04
Endpoints
Primary
Progression-free survival
Secondary
Disease Control Rate
Objective Response Rate
Duration of Response
Overall Survival
Time to Subsequent Therapy
Beyond the preview
Go deeper on NCT06652048.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06652048.